Omitting donepezil is hardly a hardshipBMJ 2007; 335 doi: http://dx.doi.org/10.1136/bmj.39388.433137.1F (Published 08 November 2007) Cite this as: BMJ 2007;335:954
- Thomas E Finucane, professor of medicine
- Johns Hopkins University School of Medicine, Burton Pavilion, 5505 Hopkins Bayview Circle, Baltimore, MD 21224, USA
To condemn the National Institute for Health and Clinical Excellence (NICE) as ageist when it limits access to donepezil is to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial